Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic study of Tarceva in metastatic or locally advanced head and neck squamous cell carcinoma
2005-003814-14Phase 2Active
- Sponsor
- Unidad Integral de Investigación en OncologÃa, S.L.
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Unidad Integral de Investigación en OncologÃa, S.L. Primary endpoint: Relationship between response rate and CA repeat number in EGFR intron 1. Started Jan 2006; status: active.
02
Drugs
erlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2005-003814-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003814-14.